The current standard-of-care adjuvant treatment for patients with colorectal cancer (CRC)
comprises a fluoropyrimidine (5-fluorouracil or capecitabine) as a single agent or in …

Background: 5-Fluorouracil (FU) is one of the most commonly used cytostatic drugs in the
systemic treatment of cancer. Treatment with FU may cause severe or life-threatening side …

Colorectal cancer (CRC) is the third most common tumour in men and the second in women,
accounting for 10% of all tumour types worldwide. Incidence is 25% higher in males and …

The circadian clock is a critical regulator of immunity, and this circadian control of immune
modulation has an essential function in host defense and tumor immunosurveillance. Here …

Despite advances in the field of pharmacogenetics (PGx), clinical acceptance has remained
limited. The Dutch Pharmacogenetics Working Group (DPWG) aims to facilitate PGx …

Fluoropyrimidines are widely used in the treatment of several types of solid tumors. Although
most often well tolerated, severe toxicity is encountered in~ 20–30% of the patients …

Background Adjuvant fluoropyrimidine-based chemotherapy substantially reduces
recurrence and mortality after resection of stage 3 colon cancer. While standard doses of 5 …

Simple Summary 5-Fluorouracil (5-FU) is a chemotherapy drug that is commonly used to
treat multiple cancers. Many people who are treated with 5-FU experience severe toxicity to …

Background The main cause for fluoropyrimidine-related toxicity is deficiency of the
metabolizing enzyme dihydropyrimidine dehydrogenase (DPD). In 2020, the European …

The dihydropyrimidine dehydrogenase enzyme (DPD, encoded by the gene DPYD) plays a
key role in the metabolism of fluoropyrimidines. DPD deficiency occurs in 4–5% of the …